NCT07366944 PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes
| NCT ID | NCT07366944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Polycystic Ovary Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-12-05 |
| Primary Completion | 2026-06-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-12-05 with a primary completion date of 2026-06-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Women with polycystic ovarian syndrome (PCOS) may complain dryness of their eyes especially obese ones. lifestye changes are main treatrment fro both problems
Eligibility Criteria
Inclusion Criteria: * PCOS women * obese class I * bilateral dryness of eye Exclusion Criteria: * liver disoease * cardiac disease * renal disease
Contact & Investigator
Ali MA Ismail, lecturer
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT07366944 clinical trial?
This trial is open to female participants only, aged 30 Years or older, up to 40 Years, studying Polycystic Ovary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07366944 currently recruiting?
Yes, NCT07366944 is actively recruiting participants. Contact the research team at ali.mohamed@pt.cu.edu.eg for enrollment information.
Where is the NCT07366944 trial being conducted?
This trial is being conducted at Giza, Egypt.
Who is sponsoring the NCT07366944 clinical trial?
NCT07366944 is sponsored by Cairo University. The principal investigator is Ali MA Ismail, lecturer at Cairo University. The trial plans to enroll 40 participants.